Preclinical WebsiteClinical Website

Amyloid Model Overview

β-amyloid pathology and cognitive impairment are hallmarks of sporadic and familial Alzheimer's disease. While multiple APP transgenic mouse models and APP knock-in mice models of Alzheimer's disease exist, which are typically based on overexpression of APP with one or more gene mutations, they each have their respective strengths and weaknesses.

At Biospective, we have validated the ARTE10 (APP/PS1) transgenic mouse model of Alzheimer's disease. Significant advantages of these transgenic mice include:

  • Beta-amyloid (Aβ) plaque deposition beginning around 3 months-of-age, with a time-dependent increase in burden and extent
  • Fibrillar extracellular and intracellular beta-amyloid pathology
  • Parenchymal and vascular Aβ deposits
  • Robust astrogliosis and microgliosis (including activated microglia)
  • Brain and spinal cord pathology

The mouse model time course is predictable and the measures are highly reproducible.

These mice are readily available at Biospective at ages appropriate for preclinical therapeutic studies.

Amyloid Transgenic Model Generation

ARTE10 [C57BL/6NTac.CBA-Tg(Thy1-PSEN1*M146V,-APP*Swe)10Arte] (APP-PS1) homozygous mice are generated on a C57BL/6NTac background. ARTE10 is a transgenic (Tg) line with two co-integrated constructs: Thy-1 promoter specific expression the transgene coding for the 695 amino acid isoform that harbors the Swedish mutation of human amyloid precursor protein (APPsw), as well as human Presenilin 1 (PS1) carrying the M146V mutation (PS1M146V). This transgenic model expresses high concentrations of human amyloid-beta (aβ) protein and aβ peptides via proteolytic processing (e.g. via β-secretases and γ-secretases), and develops human Alzheimer's disease-like amyloid pathology due to genetic mutations within the human amyloid precursor protein (APP) and PSEN1 genes. This aβ generation (via amyloidogenic processing of APP) model has been used for non-invasive imaging of amyloid-β plaques using Amyloid PET imaging tracers.

Our Validated Amyloid Mouse Model Measures

Beta-amyloid Model mIF Scan

Multiplex immunofluorescence staining (β-amyloid, Iba-1, GFAP) from a 9 month-old APP/PS1 mouse.

AD - Beta-amyloid Model - amyloid burden Graph

Time-dependent β-amyloid plaque formation in the frontal cortex.

Learn more about our characterization of this model, our validated measures, and our Preclinical Neuroscience CRO services.

Contact Us

Discover more of our Alzheimer's Models

TAU FIBRIL SPREADING MODELS

FAQs

At what age are β-amyloid plaques initially seen?

β-amyloid plaques are initially found in the frontal cortex at ~3 month-of-age in these transgenic APP mice.

What type of neuroinflammation is seen in the APP PS1 transgenic mouse model?

We observe a very interesting spatiotemporal pattern of microgliosis (including activated microglia) and astrogliosis in this model. We have performed a detailed analysis in this Alzheimer disease model, which can be found in our Presentation - β-amyloid & the inflammatory microenvironment in an APP/PS1 mouse model of Alzheimer's disease.

Is cerebral amyloid angiopathy (CAA) seen in the APP PS1 mice?

We see extensive β-amyloid vascular pathology in this Alzheimer disease transgenic mouse model. Amyloid staining can readily be observed in the leptomeningeal and deeper parenchymal blood vessels.

What promoter is used for transgene expression in the β-amyloid mice?

The mutant human APP and PSEN1 (PS1) transgenes are expressed under control of the Thy-1 promoter.

What areas of the brain show β-amyloid plaques in the β-amyloid transgenic mouse model?

Plaques are initially found in the frontal cortex and subiculum. As the mice age, there is a well-defined spatiotemporal pattern of β-amyloid pathology with extensive plaque burden in many brain regions, including the hippocampus and thalamus. We have performed a thorough characterization of these transgenic mice from 3 to 15 months-of-age.

More Information

Let us know what you’re interested in. Our team will be happy to discuss with you!

Email us at i[email protected] or simply complete & submit the form below. 

Name*
Email*
Phone Number*
Affiliation (Company/University)*
Message*

Your privacy is important to us. We will protect your data as outlined in our Privacy Notice.

I agree to the terms in the Privacy Notice*

We use necessary cookies to make our site work. We also use other cookies to help us make improvements by measuring how you use the site or for marketing purposes. You have the choice to accept or reject them all. For more detailed information about the cookies we use, see our Privacy Notice.